Persistent and paroxysmal atrial fibrillation appear to affect short- and long-term TAVR mortality rates in different ways, according to a new study of nearly 3,000 patients. Some trends fade over time, while others remain in place after many years. 

It's clear that advanced AI algorithms will radically transform care for TAVR patients in the years ahead. For now, however, certain AI models may require too much data to be helpful on a consistent basis. 

Delaying TAVR in eligible patients with severe AS can lead to much higher healthcare costs, according to a new study of real-world Medicare data.

While multiple studies have confirmed that TAVR and surgery are associated with comparable outcomes, it is important to take an individualized approach to all treatment decisions.

The new surgical valve from Foldax was designed to limit calcification and make it so patients do not require long-term anticoagulant therapy following treatment. 

Medtronic’s TAVR technology received a significant amount of attention during the very first New York Valves conference in New York City. Research focused on patients with small annuli as well as how five-year outcomes compare to surgery. 

Researchers explored five-year data from more than 1,300 TAVR patients treated with a balloon-expandable Sapien 3 valve, sharing their findings at New York Valves 2024: The Structural Heart Summit.

Researchers developed an advanced AI model capable of extracting measurements from unprocessed CT images in seconds. It then uses those data to evaluate the patient's mortality risk if they underwent TAVR.